MétaCan
Menu
← Back to cohort

Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).

2011· article· en· W2590126529 on OpenAlexaboutno aff
Brian M. Wolpin, Eileen M. O’Reilly, Y. Ko, Lawrence S. Blaszkowsky, Mark U. Rarick, Caio Max S. Rocha Lima, Paul S. Ritch, Emily Chan, J. L. Spratlin, Teresa Macarulla, Elaine McWhirter, Denis Pezet, M. Lichinitser, Laslo Roman, Alan C. Hartford, Lynnae Jackson, M. Vincent, Leonard Reyno, María Jesús Cancelo Hidalgo

Bibliographic record

VenueJournal of Clinical Oncology · 2011
Typearticle
Languageen
FieldMedicine
TopicPancreatic and Hepatic Oncology Research
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineGemcitabineNeutropeniaInternal medicineClinical endpointPopulationGastroenterologyImmunohistochemistryPhases of clinical researchPancreatic cancerAdverse effectCancerSurgeryRandomized controlled trialClinical trialChemotherapy

Abstract

fetched live from OpenAlex

4031 Background: A is a fully human monoclonal antibody directed against prostate stem cell antigen (PSCA), a cell surface protein expressed on pancreatic cancer cells. Methods: Previously untreated pts with pathologically- confirmed mPC and ECOG performance status (PS) of 0-1 were randomized 1:2 to G (1000 mg/m2 IV over 30 minutes weekly x7, 1 week rest, then weekly x3 q4weeks) or G plus A (48 mg/kg loading dose, then 24 mg/kg q3weeks over 60 minutes IV), stratified by region (North America vs. Europe/Russia). Primary endpoint was 6-month (mo) overall survival (OS) in the intention-to-treat population. With a planned sample size of 185 pts, the study was designed to detect an improvement in 6-mo OS from 45% to 65% with 90% power and one-sided α=0.10. Tumor samples were collected for pre-planned secondary analyses by PSCA expression. Results: 196 pts (63 in G arm, 133 in G+A arm) were enrolled from 04/09-05/10 at 55 centers in U.S., Canada, Spain, France, and Russia. For G/G+A arms: median age 63/62 years, male 40/56%, PS 1 83/73%, deaths to date 73/67%. Grade 3/4 adverse events (G/G+A; %): any 63/78%, neutropenia 14/26%, thrombocytopenia 2/9%, and pulmonary embolism 2/6%. Tumor tissue was available from 118 pts (60%) for immunohistochemistry (IHC): 64 pts strong/moderate (pos) and 54 weak/no staining (neg) for PSCA. Efficacy data for 6-mo OS are shown in the table. Disease control rates (PR+SD) and 95% CI were 49% (36, 62) for G arm and 50% (41, 58) for G+A arm in the full population, and 57% (34, 78) for G arm and 70% (54, 83) for G+A arm in the PSCA pos population. Conclusions: The addition of A to G is well-tolerated and resulted in a trend toward improved 6-mo OS, primarily in patients with moderate or strong tumor PSCA expression. Follow-up is ongoing for secondary endpoints. Population 6-mo OS (%) (95% CI) Difference (95% CI) P value* G G+A (G+A) - A Full 44 (32, 58) 56 (47, 64) 11 (-4, 26) 0.07 PSCA pos 57 (34, 78) 74 (59, 87) 17 (-10, 42) 0.08 PSCA neg 32 (13, 57) 34 (19, 52) 3 (-25, 30) 0.42 PSCA not available 44 (23, 66) 55 (41, 68) 11 (-13, 35) 0.19 *One-sided Cochran-Mantel-Haenszel test.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.296
GPT teacher head0.532
Teacher spread0.236 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicPancreatic and Hepatic Oncology Research→French-language works237,207→